论文部分内容阅读
本文报告在加或不加激活系统S-9组分情况下,甲孕环酯诱发人体淋巴细胞姐妹染色单体互换的离体效应。结果表明,在加或不加激活系统S-9组分中,每毫升培液含甲孕环酯15和150微克时,每个细胞的SCE 率在1—15之间(平均5.79±2.45—7.92±2.96),与对照组之间的差异无统计学意义(对照组SCE 率为2-14,平均6.56±3.89—6.68±3.18)。当含甲孕环酯300微克时,每个细胞的SCE 率为5—18(平均9.76±3.33—10.36±2.42),明显高于对照组,两者之间差异显著(P<0.05)。阳性诱变剂环磷酰胺使每个细胞的SCE 率在5—40(平均12.27±4.19—26.36±7.01),均高于甲孕环酯组,它们之间的差异在统计学上有显著意义(P<0.05)。提示甲孕环酯在S-9组分激活下未能转化为有活性的诱变剂或潜在的致癌剂,表明甲孕环酯是一种较安全的长效口服避孕药。
This article reports the in vitro effects of meso-cyclodextrin-induced sister chromatid exchange of human lymphocytes with or without the activation of the S-9 component of the system. The results showed that the SCE rate per cell was between 1 and 15 (mean 5.79 ± 2.45 - 7.92 ± 2.96). There was no significant difference with the control group (control group SCE rate was 2-14, average 6.56 ± 3.89-6.68 ± 3.18). The SCE rate of each cell ranged from 5 to 18 (average 9.76 ± 3.33-10.36 ± 2.42), which was significantly higher than that of the control group (P <0.05). Cyclophosphamide, a positive mutagen, resulted in a statistically significant SCE rate of 5-40 per cell (mean, 12.27 ± 4.19-26.36 ± 7.01) (P <0.05). Suggesting that meconazole did not convert to active mutagens or potential carcinogens when S-9 components were activated, indicating that mepirtone is a safer long-acting oral contraceptive.